1	Article Summary Line: In South Africa, after a third wave of SARS-CoV-2 infections,
2	seroprevalence was 60% in a rural and 70% in an urban community, with case-to-infection, -
3	hospitalization and -fatality ratios similar to the second wave.
4	Running title: SARS-CoV-2 seroprevalence, South Africa, 2021
5	Keywords: SARS-CoV-2, seroprevalence, case-to-infection ratio, case-to-hospitalization
6	ratio, case-to-fatality ratio
7	
8	SARS-CoV-2 seroprevalence in a rural and urban community household cohort in
9	South Africa, after the third wave, April-November 2021
10	Jackie Kleynhans (MPH), Stefano Tempia (PhD), Nicole Wolter (PhD), Anne von Gottberg
11	(PhD), Jinal N. Bhiman (PhD), Amelia Buys (MTech), Jocelyn Moyes (MD), Meredith L.
12	McMorrow (MD), Kathleen Kahn (PhD), F. Xavier Gómez-Olivé (PhD), Stephen Tollman
13	(PhD), Neil A. Martinson (MD), Floidy Wafawanaka (MSc), Limakatso Lebina (MD),
14	Jacques du Toit (MD), Waasila Jassat (MD), Mzimasi Neti (MPH), Marieke Brauer (MMed
15	Path), Cheryl Cohen (PhD), for the PHIRST-C Group ¹
16	Author affiliations
17	National Institute for Communicable Diseases of the National Health Laboratory Service,
18	Johannesburg, South Africa (J. Kleynhans, S. Tempia, N. Wolter, A. von Gottberg, J.N.
19	Bhiman, A. Buys, J. Moyes, W. Jassat, M. Neti, C. Cohen)
20	University of the Witwatersrand, Johannesburg, South Africa (J. Kleynhans, S. Tempia, N.
21	Wolter, A. von Gottberg, J.N. Bhiman, J. Moyes, C. Cohen)
22	Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America (S.
23	Tempia, M.L. McMorrow)
24	Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa (M.L.
25	McMorrow)

Page **1** of **8**

- 26 MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), University
- 27 of the Witwatersrand, Johannesburg, South Africa (K. Kahn, F.X. Gómez-Olivé, S. Tollman,
- 28 F. Wafawanaka, J. du Toit)
- 29 Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South
- 30 Africa (N.A. Martinson, L. Lebina)
- 31 Johns Hopkins University Center for TB Research, Baltimore, Maryland, United States of
- 32 America (N.A. Martinson)
- 33 Africa Health Research Institute, Durban, South Africa (L. Lebina)
- 34 Ampath Pathology, Pretoria, South Africa (M. Brauer)
- ¹Additional members of the PHIRST-C group who contributed to this manuscript are listed at
- 36 the end of this article
- **37 Abstract (words 50/50)**
- By November 2021, after the third SARS-CoV-2 wave in South Africa, seroprevalence was
- 39 60% (95%CrI 56%-64%) in a rural and 70% (95%CrI 56%-64%) in an urban community;
- 40 highest in individuals aged 13-18 years. High seroprevalence prior to Omicron emergence
- 41 may have contributed to reduced severity observed in the 4th wave.

42

43 Word count (756/800)

South Africa so far experienced four waves of SARS-CoV-2 infection, the fourth dominated
by the Omicron variant of concern (1). Data on the proportion of the population with
serologic evidence of previous infection at the time of Omicron emergence are important to
contextualise the observed rapid increases and subsequent quick decline in case numbers, (1)
as well as the lower severity compared to previous variants (2).

49 We previously described the seroprevalence of SARS-CoV-2 in the PHIRST-C cohort in a rural and an urban community at five time points, from July 2020 to March 2021 (3). Using 50 the same methods (Appendix), we report seroprevalence at four additional time points 51 52 through November 27, 2021, spanning the third Delta-dominated wave (Appendix Figure 1), ending the week Omicron was identified (4). We tested sera using the Roche Elecsys® Anti-53 SARS-CoV-2 assay (Roche Diagnostics, Rotkreuz, Switzerland); cut-off index (COI)≥1.0 54 55 considered indication of prior infection. The immunoassay detects nucleocapsid (N) antibodies, thus not detecting post-vaccination antibody responses. We obtained 56 seroprevalence 95% credible intervals (CrIs) by using Bayesian inference with 10,000 57 posterior draws (5). We estimated the age-and sex-adjusted number of infections, and age-58 adjusted diagnosed cases, hospitalizations, deaths, case-to-infection ratio (CIR), case-to-59 60 hospitalization ratio (HIR) and in-hospital and excess death case-to-fatality ratio (FIR) as 61 described previously (3) and in Appendix. Third wave infections were defined as participants 62 with a paired blood draw (BD) 5 (collected March 22 - April 11, 2021) and BD9 (collected 63 November 15 - 27, 2021) sample, seronegative at BD5 and seropositive at BD9, or seropositive at BD5 but had a \geq 2-fold higher COI in BD9 (as possible re-infections after BD5) 64 occurred, n=38, detailed in Appendix). Vaccination status was obtained through reviewing 65 66 vaccine cards kept at home. The study was approved by the University of the Witwatersrand Human Research Ethics Committee (Reference 150808) and the US Centers for Disease 67 Control and Prevention relied on local clearance (IRB #6840). 68

69 Overall, pre-third wave (BD5) SARS-CoV-2 seroprevalence adjusted for assay sensitivity 70 and specificity was 26% (95% CrI 22%-29%) in the rural and 41% (95% CrI 37%-45%) in the urban community. After the third wave (BD9), overall seroprevalence increased to 60% 71 72 (95% CrI 56%-64%) in the rural community and 70% (95% CrI 66%-74%) in the urban community (Figure, Appendix Table 1). In both communities the largest increase in 73 74 seroprevalence was seen in children aged 13-18 years, who also had the highest 75 seroprevalence of all ages after the third wave: 80% (95% CrI 70%-88%) in the rural community and 83% (95% CrI 73%-90%) in the urban community, a 49% and 19% increase, 76 77 respectively. During the third wave of infections, the incidence at the rural site was 39% (95%CrI 24%-78 55%), resulting in a CIR of 3% (95%CI 2%-5%). There was a 0.5% (95%CI 0.3%-0.7%) HIR 79 80 and an in-hospital FIR of 0.1% (95%CI 0.1%-0.2%) and an excess deaths FIR of 0.5% (95%CI 0.4%-0.8%, Figure and Appendix Figure 2). 81 82 In the urban community the incidence during the third wave was 40% (95%CrI 26%-54%). There was a 5% (95%CI 4%-8%) CIR and 2% (95%CI 2%-4%) HIR. The in-hospital FIR 83 was 0.4% (95% CI 0.3%-0.6%) and excess deaths FIR 0.6% (95% CI 0.4-0.9%, Figure and 84 Appendix Figure 2). 85 At the time of BD9, for those individuals in the rural community with a known vaccination 86 status, 29% (25/85) of individuals aged 35-59 years, and 38% (16/42) aged \geq 60 years were 87 fully vaccinated against SARS-CoV-2 (one dose of Johnson & Johnson or two doses of 88 Pfizer-BioNTech). In the urban community, 42% (47/111) aged 35-59 years and 58% (31/53) 89 90 aged ≥ 60 years were fully vaccinated (Appendix Table 2). 91 Taken together, by the end of November 2021, just prior to the emergence of Omicron, the 92 combined proportion of individuals with either serologic evidence of previous infection (at

any draw) and/or fully vaccinated was 62% (389/631) at the rural and 72% (411/568) at the
urban community (Appendix Table 3).

After the third wave of infections in South Africa, we observed a $\geq 60\%$ overall 95 seroprevalence due to SARS-CoV-2 infection, ranging from 43% in rural community 96 children aged <5 years to 83% in urban community children aged 13-18 years (Figure). CIF, 97 98 HIR and FIRs were similar between the second and third waves. Similar to our data, a study from Gauteng Province found seroprevalence of 56%-80% due to natural infection prior to 99 the emergence of Omicron (6). The high seroprevalence prior to Omicron emergence may 100 have contributed to reduced severity observed in the 4th wave (2). Future studies examining 101 SARS-CoV-2 attack rates using paired serology will be important to help understand how 102 immunity affects disease severity in the population during the fourth Omicron wave. 103

104 Additional members of the PHIRST-C group who contributed to this manuscript

105 Kgaugelo Patricia Kgasago, Linda de Gouveia, Maimuna Carrim, Mignon du Plessis,

106 Retshidisitswe Kotane, Tumelo Moloantoa

107 Acknowledgements

108 All individuals participating in the study, field teams for their hard work and dedication to the

study, the laboratory teams, the PHIRST-C scientific and safety committee, the national

110 SARS-CoV-2 NICD surveillance team, NICD IT.

111 Disclaimer

- The findings and conclusions in this report are those of the authors and do not necessarilyrepresent the official position of the CDC.
- 114 Funding

115 This work was supported by the National Institute for Communicable Diseases of the

116 National Health Laboratory Service and the US Centers for Disease Control and Prevention

- 117 (cooperative agreement number 6U01IP001048-04-02 awarded to C Cohen). The funders had
 118 no role in study design, data collection and analysis, decision to publish, or preparation of the
- 119 manuscript.

120 Potential conflicts of interest

- 121 Cheryl Cohen reports receiving grant funds from US-Centers for Disease Control and
- 122 Prevention, Wellcome Trust and South African Medical Research Council. Nicole Wolter
- and Anne von Gottberg report receiving grant funds from Sanofi and Gates Foundation. All
- 124 other authors have no competing/conflict of interest.

125 Data availability

- 126 The investigators welcome enquiries about possible collaborations and requests for access to
- the dataset. Data will be shared after approval of a proposal and with a signed data access
- agreement. Investigators interested in more details about this study, or in accessing these
- 129 resources, should contact the corresponding author.

130 **References**

- 131 1. National Institute for Comminicable Diseases. COVID-19 Weekly Epidemiology Brief Week 3.
- 132 2022 26 Janaury 2022 [cited 31 Janaury 2022; Available from: https://www.nicd.ac.za/wp-
- 133 content/uploads/2022/01/COVID-19-Weekly-Epidemiology-Brief-week-3-2022.pdf
- 134 2. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the
- 135 clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. The Lancet.
- 136 2022;339(10323):437-46.

137 3. Kleynhans J, Tempia S, Wolter N, von Gottberg A, Bhiman J, Buys A, et al. SARS-CoV-2

138 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections,

139 South Africa, July 2020–March 2021. Emerging Infectious Disease journal. 2021;27(12):3020.

- 4. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of
- 141 Concern. 2021 26 November 2021 [cited 5 January 2021 5 January 2021]; Available from:
- 142 <u>https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-</u>

143 variant-of-concern

144 5. Larremore DB, Fosdick BK, Bubar KM, Zhang S, Kissler SM, Metcalf CJE, et al. Estimating

145 SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological

146 surveys. Elife. 2021;10:e64206.

Madhi SA, Kwatra G, Myers JE, Jassat W, Dhar N, Mukendi CK, et al. South African Population
 Immunity and Severe Covid-19 with Omicron Variant. medRxiv. 2021:2021.12.20.21268096.

149 Biographical Sketch

150 Jackie Kleynhans is an epidemiologist in Centre for Respiratory Diseases and Meningitis,

151 National Institute for Communicable Diseases. She holds a Master's degree in Microbiology

and Masters of Public Health from the University of Pretoria, and is an alumnus of the South

153 African Field Epidemiology Training Programme. Her interests include the epidemiology of

respiratory diseases like influenza and COVID-19, vaccine impact studies and modelling of

155 infectious disease transmission dynamics.

156 Address for correspondence

- 157 Jackie Kleynhans, Centre for Respiratory Diseases and Meningitis, National Institute for
- 158 Communicable Diseases of the National Health Laboratory Service, 1 Modderfontein Road,
- 159 Sandringham, 2192, Johannesburg, South Africa; email: jackiel@nicd.ac.za

160



161



Baseline (BD1) July 20 – September 17, 2020; second draw (BD2) September 21 – October 164

- 10, 2020; third draw (BD3) November 23 December 12, 2020; fourth draw (BD4) January, 165
- 25 February 20, 2021; fifth draw (BD5) March 22 April 11, 2021; sixth draw (BD6) May 166
- 20 June 9, 2021; seventh draw (BD7) July 19 August 5, 2021; eighth draw (BD8) 167
- September 13 25, 2021; ninth draw (BD9) November 15 27, 2021. Vertical capped lines 168
- 169 represent 95% credible interval. Seroprevalence estimates adjusted for sensitivity and
- specificity of assay. 170